ClinicalTrials.gg
RecruitingNCT06116110Updated Aug 5, 2026

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

An observational study in Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL) and Relapsed Diffuse Large B Cell Lymphoma, sponsored by Miltenyi Biomedicine GmbH. Recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Miltenyi Biomedicine GmbH · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 216 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.

Planned enrollment
27th of 66
150 · median 84
Started
2024
with 27 others
Observational
66 of 1,131
12 open now
Primary completion
2041-12
later than 215 of 215 live
Registered
1,047th of 1,131
by date

Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 27th largest by planned enrollment of the 66 observational ones that give a count, is one of 28 that started in 2024, is one of 66 observational ones, reaches primary completion later than 215 of the 215 other live ones, and was the 1,047th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, or all of them as a file.
02

Study summary

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

Read the detailed description

This is a non-therapeutic study design. After successful screening, subjects will be monitored for potential gene therapy-related adverse events for up to 15 years post MB-CART2019.1 infusion. Subjects will be assessed yearly for the occurrence of delayed adverse events (AEs), monitored for replication competent lentivirus (RCL) and assessed for long term efficacy as well as CAR-T persistence.

03

Conditions studied

  • Non Hodgkin Lymphoma
  • Refractory Diffuse Large B Cell Lymphoma (DLBCL)
  • Relapsed Diffuse Large B Cell Lymphoma
  • High Grade B-cell Lymphoma
  • Central Nervous System Lymphoma
  • Primary Mediastinal B-cell Lymphoma (PMBCL)

Browse trials for

Keywords

  • Chimeric antigen receptor
  • CAR T
  • CD19
  • CD20
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's planned enrollment of 150 is close to the median of 150 across 186 observational studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Miltenyi Biomedicine GmbH is the lead sponsor of 20 studies on the registry; 14 are open to participants now.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have received MB-CART2019.1

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Received zamtocabtagene autoleucel in a North American Miltenyi Biomedicine-sponsored clinical study and have not withdrawn consent to be followed or been deemed lost to follow-up.
  • Provided written to participate in this study.

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Long-term Follow-Up

    No intervention

    Other: Long-term Follow-Up

Interventions

  • OtherLong-term Follow-Up

    No intervention

07

What researchers measure

Primary outcomes

  1. Number of subjects with new or recurrence of pre-existing malignancy

    Time frame: Up to 15 years

  2. Number of subjects with new incidence or exacerbation of a pre-existing neurological disorder

    Time frame: Up to 15 years

  3. Number of subjects with new incidence or exacerbation of pre-existing rheumatologic or other autoimmune disorders

    Time frame: Up to 15 years

  4. Number of subjects with new incidence of Grade ≥ 3 hematologic disorders

    Time frame: Up to 15 years

  5. Number of subjects with related AEs, related SAEs, and all AESIs

    AESIs will be collected

    Time frame: Up to 15 years

Secondary outcomes

  1. Number of subjects with measurable replication competent lentivirus in peripheral blood (if positive at study entry)

    Peripheral blood samples may be collected for RCL assessment

    Time frame: Up to 15 years

  2. Duration of zamtocabtagene autoleucel persistence

    Peripheral blood samples will be collected to test for CAR T cells

    Time frame: Up to 15 years

  3. Objective Response Rate (ORR)

    ORR for subjects who did not have progressive disease at their last assessment in the parent study; will be assessed by IRC and Investigator using Lugano 2014 Criteria for DLBCL and SCNSL and using IPCG Criteria (Abrey 2005) for PCNSL

    Time frame: Up to 15 years

  4. Overall Survival

    OS, measured from the date of zamtocabtagene autoleucel infusion to the date of the subject's death or the date the subject is last to known to be alive

    Time frame: Up to 15 years

  5. To determine the number of subjects who relapse after zamtocabtagene autoleucel infusion during LTFU

    Disease relapse: Number of subjects who enter the study as responders and relapse

    Time frame: Up to 15 years

  6. To assess immune reconstitution based on the recovery of total lymphocytes

    Change from baseline in peripheral B cell and lymphocyte levels

    Time frame: Up to 15 years

08

Study locations

10 of 11 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2041, 210 months after the start.

Of 66 observational studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 114. This study's planned 210 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2023
First posted
Nov 3, 2023
StartActual
May 15, 2024
Primary completionEst.
Dec 1, 2041
CompletionEst.
Dec 1, 2041
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06116110
Lead sponsor
Miltenyi Biomedicine GmbH
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
May 15, 2024
Primary completion
Dec 1, 2041 (estimated)
Completion
Dec 1, 2041 (estimated)
Last update
Aug 5, 2026

Study contacts

Sadie Swift
Contact
clinicaltrials@miltenyi.com
617-218-0044
Paris Jamiel
Contact
clinicaltrials@miltenyi.com
617-218-0044
Remi Kaleta, MD
study director · Miltenyi Biomedicine GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion